

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS VACCINE
PROJECT WITH BILL & MELINDA GATES FOUNDATION

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that the Group and Bill & Melinda Gates Foundation (the “**Foundation**”) has entered into a Grant Agreement, pursuant to which with the mutually agreed request, the Foundation agreed to provide over US\$2 million in total to support the development of the Recombinant Poliomyelitis Vaccine, a polio vaccine candidate based on virus-like particle (“**VLP**”) of the Company (“**Project CS-2036**”). The payments are subject to, among others, the payment schedule associated with the completion of various development targets/milestones.

Based on the protein structure design and VLP assembly technology of the Company, CS-2036 vaccine candidate expects to contribute substantially to global polio control including post-eradication. The CS-2036 candidate is a non-infectious polio VLP vaccine with good safety and immunogenicity profiles that does not rely on live virus in the manufacturing process. Unlike existing attenuated and inactivated polio vaccines, non-infectious polio VLP vaccines are recommended by the World Health Organization as one of the preferred vaccines for polio in the future.

To achieve the accessibility and affordability of polio vaccines in developing or underdeveloped countries, the Company will ensure that the knowledge and information gained from Project CS-2036 will be promptly and broadly disseminated and the funded developments will be made available and accessible at an affordable price to people most in need within developing countries.

We cannot guarantee that we will ultimately develop or commercialize CS-2036 successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, October 24, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.